Abstract
AbstractIn the era of precision medicine, the selection of cancer treatment relies increasingly on the identification of genomic alterations; however, it is not yet clear how frequently genomic profiling should be performed over the disease course of a patient with metastatic cancer. A large‐scale study investigates the genomic evolution of cancer metastases under therapeutic pressure and finds that the actionable genome has remained relatively stable. The findings support the sufficiency of a single biopsy of cancer metastasis for therapeutic decision‐making.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
